Miraca Life Sciences Enhances Summary Reports to Help GI Physicians Improve Endoscopic Quality, Meet ADR Reporting Requirements

Detailed, coded data will provide additional information to gastroenterologists on their colonoscopy results.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
“We are proud to lead the way and provide this new level of diagnostic reporting," said Richard Lash, MD, Chief Medical Officer for Miraca Life Sciences.

IRVING, Texas (PRWEB) May 08, 2014

Miraca Life Sciences (MLS), the nation’s largest independent anatomic pathology lab, has enhanced the pathologic summary reports it provides to gastroenterologists, which can be used in the calculation of their adenoma detection rate (ADR). The more detailed and coded data MLS now provides will help these physicians to assess the quality of their endoscopic procedures and meet the reporting requirements of the GI Quality Improvement Consortium (GIQuIC) registry.

The adenoma detection rate (ADR) is a common measure of endoscopic quality that is used increasingly by payers and regulatory agencies in the assessment of gastroenterology practices. The pathologic data summaries provided by MLS can now be used by GI physicians in the calculation of their ADR and other quantitative measures related to colonoscopic polypyectomy.

To improve the accuracy of its summary reports, MLS now uses coded data to enter diagnoses. In addition, MLS’s summary reports now include the following polyp categories, which are used in the GIQuIC registry developed jointly by the American College of Gastroenterology (ACG) and American Society for Gastrointestinal Endoscopy (ASGE):

  •     Adenomatous polyps:
     - Non-advanced adenomas
     - Advanced adenomas (villous morphology, high-grade dysplasia)
  •     Serrated Polyps:
     - Sessile serrated polyp with no dysplasia
     - Sessile serrated polyp with dysplasia or traditional serrated polyp
  •     Hyperplastic polyps

To further assist physicians, MLS’s summary reports also now include data on patient gender and age.

“Specific and standardized data has become increasingly important for clinicians as they are asked to report patient outcomes to payors, regulatory agencies and registries. MLS’s highly structured approach, utilizing consensus diagnostic terminology and criteria, will ensure that clinicians will not only get clinically relevant diagnoses, they will be compliant with regulatory requirements,” said Richard Lash, MD, Chief Medical Officer for Miraca Life Sciences. “We are proud to lead the way and provide this new level of diagnostic reporting, while creating a powerful database to help clinicians and pathologists improve patient outcomes.”

About Miraca Life Sciences
Miraca Life Sciences specializes in the development and commercialization of the highest quality academic pathology services, primarily in the fields of dermatology, hematology, gastroenterology and urology. The company’s core team of more than 90 academic-caliber specialists utilizes state-of-the-art pathology laboratories currently headquartered in Irving, Texas, and throughout the United States to serve more than 5,500 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.


Contact